Skip to main content

Peer Review reports

From: Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial

Original Submission
12 Dec 2023 Submitted Original manuscript
1 Jan 2024 Reviewed Reviewer Report
6 Jan 2024 Reviewed Reviewer Report
7 Feb 2024 Author responded Author comments - Zhihong Lu
8 Feb 2024 Reviewed Reviewer Report
11 Feb 2024 Reviewed Reviewer Report
Resubmission - Version 2
7 Feb 2024 Submitted Manuscript version 2
Publishing
11 Feb 2024 Editorially accepted
16 Apr 2024 Article published 10.1186/s10194-024-01731-4

You can find further information about peer review here.

Back to article page